|Preferred IUPAC name
3D model (JSmol)
|E number||E363 (antioxidants, ...)|
|Molar mass||118.09 g·mol−1|
|Melting point||184–190 °C (363–374 °F; 457–463 K)|
|Boiling point||235 °C (455 °F; 508 K)|
|58 g/L (20 °C) or 100 mg/mL|
|Solubility in Methanol||158 mg/mL|
|Solubility in Ethanol||54 mg/mL|
|Solubility in Acetone||27 mg/mL|
|Solubility in Glycerol||50 mg/mL|
|Solubility in Ether||8.8 mg/mL|
|Acidity (pKa)||pKa1 = 4.2|
pKa2 = 5.6
|Flash point||206 °C (403 °F; 479 K)|
Related carboxylic acids
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Succinic acid (//) is a dicarboxylic acid with the chemical formula (CH2)2(CO2H)2. The name derives from Latin succinum, meaning amber. In living organisms, succinic acid takes the form of an anion, succinate, which has multiple biological roles as a metabolic intermediate being converted into fumarate by the enzyme succinate dehydrogenase in complex 2 of the electron transport chain which is involved in making ATP, and as a signaling molecule reflecting the cellular metabolic state. Succinate is generated in mitochondria via the tricarboxylic acid cycle (TCA), an energy-yielding process shared by all organisms.:Section 17.1 Succinate can exit the mitochondrial matrix and function in the cytoplasm as well as the extracellular space, changing gene expression patterns, modulating epigenetic landscape or demonstrating hormone-like signaling. As such, succinate links cellular metabolism, especially ATP formation, to the regulation of cellular function. Dysregulation of succinate synthesis, and therefore ATP synthesis, happens in some genetic mitochondrial diseases, such as Leigh syndrome, and Melas syndrome, and degradation can lead to pathological conditions, such as malignant transformation, inflammation and tissue injury.
- 1 Physical properties
- 2 Production and common reactions
- 3 Applications
- 4 Biosynthesis
- 5 Cellular metabolism
- 6 Additional biologic functions
- 6.1 Succinate transporters
- 6.2 Extracellular signaling
- 6.3 Intracellular signaling
- 7 Role in human health
- 8 See also
- 9 References
- 10 External links
Succinic acid is a white, odorless solid with a highly acidic taste. In an aqueous solution, succinic acid readily ionizes to form its conjugate base, succinate (//). As a diprotic acid, succinic acid undergoes two successive deprotonation reactions:
- (CH2)2(CO2H)2 → (CH2)2(CO2H)(CO2)− + H+
- (CH2)2(CO2H)(CO2)− → (CH2)2(CO2)22− + H+
The pKa of these processes are 4.3 and 5.6, respectively. Both anions are colorless and can be isolated as the salts, e.g., Na(CH2)2(CO2H)(CO2) and Na2(CH2)2(CO2)22−. In living organisms, primarily succinate, not succinic acid, is found.
Like most simple mono- and dicarboxylic acids, it is not harmful but can be an irritant to skin and eyes.
Production and common reactions
Succinic acid can be oxidized to fumaric acid or be converted to diesters, such as diethylsuccinate (CH2CO2CH2CH3)2. This diethyl ester is a substrate in the Stobbe condensation. Dehydration of succinic acid gives succinic anhydride. Succinate can be used to derive 1,4-butanediol, maleic anhydride, succinimide, 2-pyrrolidinone and tetrahydrofuran.
Historically, succinic acid was obtained from amber by distillation and has thus been known as spirit of amber. Today, succinic acid is generated for human use synthetically or converted from biomass via fermentation. Common industrial routes of synthesis include partial hydrogenation of maleic acid, oxidation of 1,4-butanediol, and carbonylation of ethylene glycol. Succinate is also produced petrochemically from butane via maleic anhydride. Additionally, genetic engineering of microorganisms, such as Escherichia coli or Saccharomyces cerevisiae, has recently allowed for the high-yielding, commercial production from fermentation of glucose. Global production is estimated at 16,000 to 30,000 tons a year, with an annual growth rate of 10%.
In 2004, succinate was placed on the US Department of Energy's list of top 12 platform chemicals from biomass.
Precursor to polymers, resins, and solvents
Succinic acid is a precursor to some polyesters and a component of some alkyd resins. 1,4-Butanediol (BDO) can be synthesized using succinic as a precursor. The automotive and electronics industries heavily rely on BDO to produce connectors, insulators, wheel covers, gearshift knobs and reinforcing beams. Succinic acid also serves as the bases of certain biodegradable polymers, which are of interest in tissue engineering applications.
Acylation with succinic acid is called succination. Oversuccination occurs when more than one succinate adds to a substrate.
Food and dietary supplement
As a food additive and dietary supplement, succinic acid is generally recognized as safe by the U.S. Food and Drug Administration. Succinic acid is used primarily as an acidity regulator in the food and beverage industry. It is also available as a flavoring agent, contributing a somewhat sour and astringent component to umami taste. As an excipient in pharmaceutical products, it is also used to control acidity or as a counter ion. Drugs involving succinate include metoprolol succinate, sumatriptan succinate, Doxylamine succinate or solifenacin succinate.
Tricarboxylic acid (TCA) cycle
Succinate is a key intermediate in the tricarboxylic acid cycle, a primary metabolic pathway used to produce chemical energy in the presence of O2. Succinate is generated from succinyl-CoA by the enzyme succinyl-CoA synthetase in a GTP/ATP-producing step::Section 17.1
Succinyl-CoA + NDP + Pi → Succinate + CoA + NTP
Succinate + FAD → Fumarate + FADH2
SDH also participates in the mitochondrial electron transport chain, where it is known as respiratory Complex 2. This enzyme complex is a 4 subunit membrane-bound lipoprotein which couples the oxidation of succinate to the reduction of ubiquinone via the intermediate electron carriers FAD and three 2Fe-2S clusters. Succinate thus serves as a direct electron donor to the electron transport chain, and itself is converted into fumarate.
Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
Reductive branch of the TCA cycle
Succinate can alternatively be formed by reverse activity of SDH. Under anaerobic conditions certain bacteria such as A. succinogenes, A. succiniciproducens and M. succiniciproducens, run the TCA cycle in reverse and convert glucose to succinate through the intermediates of oxaloacetate, malate and fumarate. This pathway is exploited in metabolic engineering to net generate succinate for human use. Additionally, succinic acid produced during the fermentation of sugar provides a combination of saltiness, bitterness and acidity to fermented alcohols.
Accumulation of fumarate can drive the reverse activity of SDH, thus enhancing succinate generation. Under pathological and physiological conditions, the malate-aspartate shuttle or the purine nucleotide shuttle can increase mitochondrial fumarate, which is then readily converted to succinate.
Succinate is also a product of the glyoxylate cycle, which converts two two-carbon acetyl units into the four-carbon succinate. The glyoxylate cycle is utilized by many bacteria, plants and fungi and allows these organisms to subsist on acetate or acetyl CoA yielding compounds. The pathway avoids the decarboxylation steps of the TCA cycle via the enzyme isocitrate lyase which cleaves isocitrate into succinate and glyoxylate. Generated succinate is then available for either energy production or biosynthesis.:Section 17.4
Succinate is the re-entry point for the gamma-aminobutyric acid (GABA) shunt into the TCA cycle, a closed cycle which synthesizes and recycles GABA. The GABA shunt serves as an alternate route to convert alpha-ketoglutarate into succinate, bypassing the TCA cycle intermediate succinyl-CoA and instead producing the intermediate GABA. Transamination and subsequent decarboxylation of alpha-ketoglutarate leads to the formation of GABA. GABA is then metabolized by GABA transaminase to succinic semialdehyde. Finally, succinic semialdehyde is oxidized by succinic semialdehyde dehydrogenase (SSADH) to form succinate, re-entering the TCA cycle and closing the loop. Enzymes required for the GABA shunt are expressed in neurons, glial cells, macrophages and pancreatic cells.
Succinate is produced and concentrated in the mitochondria and its primary biological function is that of a metabolic intermediate.:Section 17.1 All metabolic pathways that are interlinked with the TCA cycle, including the metabolism of carbohydrates, amino acids, fatty acids, cholesterol, and heme, rely on the temporary formation of succinate. The intermediate is made available for biosynthetic processes through multiple pathways, including the reductive branch of the TCA cycle or the glyoxylate cycle, which are able to drive net production of succinate. In rodents, mitochondrial concentrations are approximately ~0.5 mM while plasma concentration are only 2–20 μM.
The activity of succinate dehydrogenase (SDH), which interconverts succinate into fumarate participates in mitochondrial reactive oxygen species (ROS) production by directing electron flow in the electron transport chain. Under conditions of succinate accumulation, rapid oxidation of succinate by SDH can drive reverse electron transport (RET). If mitochondrial respiratory complex III is unable to accommodate excess electrons supplied by succinate oxidation, it forces electrons to flow backwards along the electron transport chain. RET at mitochondrial respiratory complex 1, the complex normally preceding SDH in the electron transport chain, leads to ROS production and creates a pro-oxidant microenvironment.
Additional biologic functions
This article relies too much on references to primary sources. (March 2017) (Learn how and when to remove this template message)
In addition to its metabolic roles, succinate serves as an intracellular and extracellular signaling molecule. Extra-mitochondrial succinate alters the epigenetic landscape by inhibiting the family of 2-oxogluterate-dependent dioxygenases. Alternative, succinate can be released into the extracellular milieu and the blood stream where it is recognized by target receptors. In general, leakage from the mitochondria requires succinate overproduction or underconsumption and occurs due to reduced, reverse or completely absent activity of SDH or alternative changes in metabolic state. Mutations in SDH, hypoxia or energetic misbalance are all linked to an alteration of flux through the TCA cycle and succinate accumulation. Upon exiting the mitochondria, succinate serves as a signal of metabolic state, communicating to neighboring cells how metabolically active the originating cell population is. As such, succinate links TCA cycle dysfunction or metabolic changes to cell-cell communication and to oxidative stress-related responses.
Succinate requires specific transporters to move through both the mitochondrial and plasma membrane. Succinate exits the mitochondrial matrix and passes through the inner mitochondrial membrane via dicarboxylate transporters, primarily SLC25A10, a succinate-fumarate/malate transporter. In the second step of mitochondrial export, succinate readily crosses the outer mitochondrial membrane through porins, nonspecific protein channels that facilitate the diffusion of molecules less than 1.5 kDa. Transport across the plasma membrane is likely tissue specific. A key candidate transporter is INDY (I'm not dead yet), a sodium-independent anion exchanger, which moves both dicarboxylate and citrate into the bloodstream.
Extracellular succinate can act as a signaling molecule with hormone-like function, targeting a variety of tissues such as blood cells, adipose tissue, immune cells, the liver, the heart, the retina and primarily the kidney. The G-protein coupled receptor, GPR91 also known as SUCNR1, serves as the detector of extracellular succinate. Arg99, His103, Arg252, and Arg281 near the center of the receptor generate a positively charged binding site for succinate. The ligand specificity of GPR91 was rigorously tested using 800 pharmacologically active compounds and 200 carboxylic acid and succinate-like compounds, all of which demonstrated significantly lower binding affinity. Overall, the EC50 for succinate-GPR91 is in the 20–50 uM range. Depending on the cell type, GPR91 can interact with multiple G proteins, including Gs, Gi and Gq, and enabling a multitude of signaling outcomes.
Effect on adipocytes
Effect on the liver and retina
Succinate signaling often occurs in response to hypoxic conditions. In the liver, succinate serves as a paracrine signal, released by anoxic hepatocytes, and targets stellate cells via GPR91. This leads to stellate cell activation and fibrogenesis. Thus, succinate is thought to play a role in liver homeostasis. In the retina, succinate accumulates in retinal ganglion cells in response to ischemic conditions. Autocrine succinate signaling promotes retinal neovascularization, triggering the activation of angiogenic factors such as endothelial growth factor (VEGF).
Effect on the heart
Extracellular succinate regulates cardiomyocyte viability through GPR91 activation; long-term succinate exposure leads to pathological cardiomyocyte hypertrophy. Stimulation of GPR91 triggers at least two signaling pathways in the heart: a MEK1/2 and ERK1/2 pathway that activates hypertrophic gene expression and a phospholipase C pathway which changes the pattern of Ca2+ uptake and distribution and triggers CaM-dependent hypertrophic gene activation.
Effect on immune cells
SUCNR1 is highly expressed on immature dendritic cells, where succinate binding stimulates chemotaxis. Furthermore, SUCNR1 synergizes with toll-like receptors to increase the production of proinflammatory cytokines such as TNF alpha and interleukin-1beta. Succinate may enhance adaptive immunity by triggering the activity of antigen-presenting cells that, in turn, activate T-cells.
Effect on platelets
SUCNR1 is one of the highest expressed G protein-coupled receptors on human platelets, present at levels similar to P2Y12, though the role of succinate signaling in platelet aggregation is debated. Multiple studies have demonstrated succinate-induced aggregation, but the effect has high inter-individual variability.
Effect on the kidneys
Succinate serves as a modulator of blood pressure by stimulating renin release in macula densa and juxtaglomerular apparatus cells via GPR91. Therapies targeting succinate to reduce cardiovascular risk and hypertension are currently under investigation.
Accumulation of either fumarate or succinate reduces the activity of 2-oxogluterate-dependent dioxygenases, including histone and DNA demethylases, prolyl hydroxylases and collagen prolyl-4-hydroxyalses, through competitive inhibition. 2-oxoglutarate-dependent dioxygenases require an iron cofactor to catalyze hydroxylations, desaturations and ring closures. Simultaneous to substrate oxidation, they convert 2-oxglutarate, also known as alpha-ketoglutarate, into succinate and CO2. 2-oxoglutarate-dependent dioxygenases bind substrates in a sequential, ordered manner. First, 2-oxoglutarate coordinates with an Fe(II) ion bound to a conserved 2-histidinyl–1-aspartyl/glutamyl triad of residues present in enzymatic center. Subsequently, the primary substrate enters the binding pocket and lastly dioxygen binds to the enzyme-substrate complex. Oxidative decarboxylation then generates a ferryl intermediate coordinated to succinate, which serves to oxidize the bound primary substrate. Succinate may interfere with the enzymatic process by attaching to the Fe(II) center first, prohibiting the binding of 2-oxoglutarate. Thus, via enzymatic inhibition, increased succinate load can lead to changes in transcription factor activity and genome-wide alterations in histone and DNA methylation.
Succinate and fumarate inhibit the TET (ten-eleven translocation) family of 5-methylcytosine DNA modifying enzymes and the JmjC domain-containing histone lysine demethylase (KDM). Pathologically elevated levels of succinate lead to hypermethylation, epigenetic silencing and changes in neuroendocrine differentiation, potentially driving cancer formation.
Succinate inhibition of prolyl hydroxylases (PHDs) stabilizes the transcription factor hypoxia inducible factor (HIF)1α. PHDs hydroxylate proline in parallel to oxidatively decarboxylating 2-oxyglutarate to succinate and CO2. In humans, three HIF prolyl 4-hydroxylases regulate the stability of HIFs. Hydroxylation of two prolyl residues in HIF1α facilitates ubiquitin ligation, thus marking it for proteolytic destruction by the ubiquitin/proteasome pathway. Since PDHs have an absolute requirement for molecular oxygen, this process is suppressed in hypoxia allowing HIF1α to escape destruction. High concentrations of succinate will mimic the hypoxia state by suppressing PHDs, therefore stabilizing HIF1α and inducing the transcription of HIF1-dependent genes even under normal oxygen conditions. HIF1 is known to induce transcription of more than 60 genes, including genes involved in vascularization and angiogenesis, energy metabolism, cell survival, and tumor invasion.
Role in human health
Metabolic signaling involving succinate can be involved in inflammation via stabilization of HIF1-alpha or GPR91 signaling in innate immune cells. Through these mechanisms, succinate accumulation has been shown to regulate production of inflammatory cytokines. For dendritic cells, succinate functions as a chemoattractant and increases their antigen-presenting function via receptor stimulated cytokine production. In inflammatory macrophages, succinate-induced stability of HIF1 results in increased transcription of HIF1-dependent genes, including the pro-inflammatory cytokine interleukin-1β. Other inflammatory cytokines produced by activated macrophages such as tumor necrosis factor or interleukin 6 are not directly affected by succinate and HIF1. The mechanism by which succinate accumulates in immune cells is not fully understood. Activation of inflammatory macrophages through toll-like receptors induces a metabolic shift towards glycolysis. In spite of a general downregulation of the TCA cycle under these conditions, succinate concentration is increased. However, lipopolysaccharides involved in the activation of macrophages increase glutamine and GABA transporters. Succinate may thus be produced from enhanced glutamine metabolism via alpha-ketoglutarate or the GABA shunt.
Succinate is one of three oncometabolites, metabolic intermediates whose accumulation causes metabolic and non-metabolic dysregulation implicated in tumorigenesis. Loss-of-function mutations in the genes encoding succinate dehydrogenase, frequently found in hereditary paraganglioma and pheochromocytoma, cause pathological increase in succinate. SDH mutations have also been identified in gastrointestinal stromal tumors, renal tumors, thyroid tumors, testicular seminomas and neuroblastomas. The oncogenic mechanism caused by mutated SHD is thought to relate to succinate's ability to inhibit 2-oxogluterate-dependent dioxygenases. Inhibition of KDMs and TET hydroxylases results in epigenetic dysregulation and hypermethylation affecting genes involved in cell differentiation. Additionally, succinate-promoted activation of HIF-1α generates a pseudo-hypoxic state that can promote tumorneogensis by transcriptional activation of genes involved in proliferation, metabolism and angiogenesis. The other two oncometabolites, fumarate and 2-hydroxyglutarate have similar structures to succinate and function through parallel HIF-inducing oncogenic mechanisms.
Ischemia reperfusion injury
Succinate accumulation under hypoxic conditions has been implicated in the reperfusion injury through increased ROS production. During ischemia, fumarate is formed from purine nucleotide breakdown and partial reversal of the malate/aspartate shuttle. Fumarate overflow results in the production and accumulation of succinate through reverse activity of SDH. Upon reperfusion, succinate is rapidly oxidized leading to abrupt and extensive production of ROS. ROS then trigger the cellular apoptotic machinery or induce oxidative damage to proteins, membranes, organelles etc. In animal models, pharmacological inhibition of ischemic succinate accumulation ameliorated ischemia-reperfusion injury. As of 2016 the inhibition of succinate-mediated ROS production was under investigation as a therapeutic drug target.
- Nomenclature of Organic Chemistry : IUPAC Recommendations and Preferred Names 2013 (Blue Book). Cambridge: The Royal Society of Chemistry. 2014. p. 747. doi:10.1039/9781849733069-FP001. ISBN 978-0-85404-182-4.
- Record in the GESTIS Substance Database of the Institute for Occupational Safety and Health
- "Product Information Sheet: Succinic Acid" (PDF). Sigma Aldrich. Retrieved 7 November 2015.
- Chikhalia, V.; Forbes, R.T.; Storey, R.A.; Ticehurst, M. (2006-01). "The effect of crystal morphology and mill type on milling induced crystal disorder". European Journal of Pharmaceutical Sciences. 27 (1): 19–26. doi:10.1016/j.ejps.2005.08.013. ISSN 0928-0987. Check date values in:
- "Succinic Acid". Toxnet National Library of Medicine HSDB Database. 2005-01-31. Retrieved 28 May 2017.
- Tretter, Laszlo; Patocs, Attila; Chinopoulos, Christos (2016-08-01). "Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis". Biochimica et Biophysica Acta (BBA) - Bioenergetics. EBEC 2016: 19th European Bioenergetics Conference. 1857 (8): 1086–1101. doi:10.1016/j.bbabio.2016.03.012. PMID 26971832.
- Berg, JM; Tymoczko, JL; Stryer, L (2002). Biochemistry (5th ed.). New York: W H Freeman.
- Mills, Evanna; O'Neill, Luke A.J. (May 2014). "Succinate: a metabolic signal in inflammation". Trends in Cell Biology. 24 (5): 313–320. doi:10.1016/j.tcb.2013.11.008. PMID 24361092.
- Chouchani, ET; Pell, VR; Gaude, E; Aksentijević, D; Sundier, SY; Robb, EL; Logan, A; Nadtochiy, SM; Ord, EN; Smith, AC; Eyassu, F; Shirley, R; Hu, CH; Dare, AJ; James, AM; Rogatti, S; Hartley, RC; Eaton, S; Costa, AS; Brookes, PS; Davidson, SM; Duchen, MR; Saeb-Parsy, K; Shattock, MJ; Robinson, AJ; Work, LM; Frezza, C; Krieg, T; Murphy, MP (20 November 2014). "Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS". Nature. 515 (7527): 431–5. doi:10.1038/nature13909. PMC 4255242. PMID 25383517.
- "Definition of SUCCINYL". www.merriam-webster.com. Retrieved 2017-03-09.
- Louis F. Fieser; E. L. Martin; R. L. Shriner; H. C. Struck (1932). "Succinic Anhydride". Organic Syntheses. 12: 66.; Collective Volume, 2, p. 560.
- Thakker, Chandresh; Martínez, Irene; San, Ka-Yiu; Bennett, George N. (2017-03-07). "Succinate production in Escherichia coli". Biotechnology journal. 7 (2): 213–224. doi:10.1002/biot.201100061. PMC 3517001. PMID 21932253.
- Boy Cornils; Peter Lappe, "Dicarboxylic Acids, Aliphatic", Ullmann's Encyclopedia of Industrial Chemistry, Weinheim: Wiley-VCH, doi:10.1002/14356007.a08_523
- Otero, José Manuel; Cimini, Donatella; Patil, Kiran R.; Poulsen, Simon G.; Olsson, Lisbeth; Nielsen, Jens (2013-01-21). "Industrial Systems Biology of Saccharomyces cerevisiae Enables Novel Succinic Acid Cell Factory". PLOS ONE. 8 (1): e54144. doi:10.1371/journal.pone.0054144. ISSN 1932-6203. PMC 3549990. PMID 23349810.
- NNFCC Renewable Chemicals Factsheet: Succinic Acid
- "Top Value Added Chemicals from Biomass, Volume 1: Results of Screening for Potential Candidates from Sugars and Synthesis Gas" (PDF). U.S. Department of Energy. November 1, 2004. Retrieved 2013-11-12.
- Ashford's Dictionary of Industrial Chemicals (3rd ed.), 2011, p. 1517, ISBN 978-0-9522674-3-0
- "1,4-Butanediol (BDO) Market Analysis By Application (Tetrahydrofuran, Polybutylene Teraphthalate, Gamma-Butyrolactone & Polyurethanes), And Segment Forecasts To 2020". Grand View Research. September 2015. Retrieved 2015-11-18.
- Barrett, Devin G.; Yousaf, Muhammad N. (2009-10-12). "Design and Applications of Biodegradable Polyester Tissue Scaffolds Based on Endogenous Monomers Found in Human Metabolism". Molecules. 14 (10): 4022–4050. doi:10.3390/molecules14104022.
- FDA GRAS Database. Succinic acid in the FDA SCOGS Database
- Zeikus, J. G.; Jain, M. K.; Elankovan, P. (1999). "Biotechnology of succinic acid production and markets for derived industrial products". Applied Microbiology and Biotechnology. 51 (5): 545. doi:10.1007/s002530051431.
- "Overview of pharmaceutical excipients used in tablets and capsules". Modern Medicine Network. 24 October 2008. Archived from the original on 19 February 2012. Retrieved 7 November 2015.
- Dröse, Stefan (2013-05-01). "Differential effects of complex II on mitochondrial ROS production and their relation to cardioprotective pre- and postconditioning". Biochimica et Biophysica Acta (BBA) - Bioenergetics. Respiratory complex II: Role in cellular physiology and disease. 1827 (5): 578–587. doi:10.1016/j.bbabio.2013.01.004. PMID 23333272.
- Cheng, Ke-Ke; Wang, Gen-Yu; Zeng, Jing; Zhang, Jian-An (2013-04-18). "Improved Succinate Production by Metabolic Engineering". BioMed Research International. 2013: 1–12. doi:10.1155/2013/538790. ISSN 2314-6133. PMC 3652112. PMID 23691505.
- Peynaud, Emile (1984). Knowing and Making Wine.
- Haas, Robert; Cucchi, Danilo; Smith, Joanne; Pucino, Valentina; Macdougall, Claire Elizabeth; Mauro, Claudio. "Intermediates of Metabolism: From Bystanders to Signalling Molecules". Trends in Biochemical Sciences. 41 (5): 460–471. doi:10.1016/j.tibs.2016.02.003. PMID 26935843.
- Olsen, Richard W; DeLorey, Timothy M (1999). "GABA Synthesis, Uptake and Release". In Siegel, GJ; Agranoff, BW; Albers, RW; et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects (6th ed.). Philadelphia: Lippincott-Raven.
- Ariza, Ana Carolina; Deen, Peter M. T.; Robben, Joris Hubertus (2012-01-01). "The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions". Molecular and Structural Endocrinology. 3: 22. doi:10.3389/fendo.2012.00022. PMC 3355999. PMID 22649411.
- Pell, Victoria R.; Chouchani, Edward T.; Frezza, Christian; Murphy, Michael P.; Krieg, Thomas (2016-07-15). "Succinate metabolism: a new therapeutic target for myocardial reperfusion injury". Cardiovascular Research. 111 (2): 134–141. doi:10.1093/cvr/cvw100. PMID 27194563.
- de Castro Fonseca, Matheus; Aguiar, Carla J.; da Rocha Franco, Joao Antônio; Gingold, Rafael N.; Leite, M. Fatima (2016-01-01). "GPR91: expanding the frontiers of Krebs cycle intermediates". Cell Communication and Signaling. 14: 3. doi:10.1186/s12964-016-0126-1. PMC 4709936. PMID 26759054.
- Bardella, Chiara; Pollard, Patrick J.; Tomlinson, Ian (2011-11-01). "SDH mutations in cancer". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 1807 (11): 1432–1443. doi:10.1016/j.bbabio.2011.07.003. PMID 21771581.
- Gilissen, Julie; Jouret, François; Pirotte, Bernard; Hanson, Julien (2016-03-01). "Insight into SUCNR1 (GPR91) structure and function". Pharmacology & Therapeutics. 159: 56–65. doi:10.1016/j.pharmthera.2016.01.008. PMID 26808164.
- Peti-Peterdi, János; Gevorgyan, Haykanush; Lam, Lisa; Riquier-Brison, Anne (2012-06-23). "Metabolic control of renin secretion". Pflügers Archiv - European Journal of Physiology. 465 (1): 53–58. doi:10.1007/s00424-012-1130-y. ISSN 0031-6768. PMC 4574624. PMID 22729752.
- Xiao, Mengtao; Yang, Hui; Xu, Wei; Ma, Shenghong; Lin, Huaipeng; Zhu, Honguang; Liu, Lixia; Liu, Ying; Yang, Chen (2012-06-15). "Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors". Genes & Development. 26 (12): 1326–1338. doi:10.1101/gad.191056.112. ISSN 0890-9369. PMC 3387660. PMID 22677546.
- Hewitson, K. S.; Granatino, N.; Welford, R. W. D.; McDonough, M. A.; Schofield, C. J. (2005-04-15). "Oxidation by 2-oxoglutarate oxygenases: non-haem iron systems in catalysis and signalling". Philosophical Transactions of the Royal Society of London A: Mathematical, Physical and Engineering Sciences. 363 (1829): 807–828. doi:10.1098/rsta.2004.1540. PMID 15901537.
- Yang, Ming; Pollard, Patrick J. (10 June 2013). "Succinate: A New Epigenetic Hacker". Cancer Cell. 23 (6): 709–711. doi:10.1016/j.ccr.2013.05.015. PMID 23763995.
- Yang, Ming; Soga, Tomoyoshi; Pollard, Patrick J. (2013-09-03). "Oncometabolites: linking altered metabolism with cancer". The Journal of Clinical Investigation. 123 (9). doi:10.1172/JCI67228. ISSN 0021-9738. PMC 3754247. PMID 23999438.
- Koivunen, P; Hirsilä, M; Remes, AM; Hassinen, IE; Kivirikko, KI; Myllyharju, J (16 February 2007). "Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF". The Journal of Biological Chemistry. 282 (7): 4524–32. doi:10.1074/jbc.M610415200. PMID 17182618.
- Tannahill, GM; Curtis, AM; Adamik, J; Palsson-McDermott, EM; McGettrick, AF; Goel, G; Frezza, C; Bernard, NJ; Kelly, B (2013-04-11). "Succinate is a danger signal that induces IL-1β via HIF-1α". Nature. 496 (7444): 238–242. doi:10.1038/nature11986. ISSN 0028-0836. PMC 4031686. PMID 23535595.
- Kelly, Beth; O'Neill, Luke AJ (2015-07-01). "Metabolic reprogramming in macrophages and dendritic cells in innate immunity". Cell Research. 25 (7): 771–784. doi:10.1038/cr.2015.68. ISSN 1001-0602. PMC 4493277. PMID 26045163.
- Sciacovelli, Marco; Frezza, Christian (2017-03-06). "Oncometabolites: Unconventional triggers of oncogenic signalling cascades". Free Radical Biology & Medicine. 100: 175–181. doi:10.1016/j.freeradbiomed.2016.04.025. ISSN 0891-5849. PMC 5145802. PMID 27117029.
- King, A.; Selak, M. A.; Gottlieb, E. (2006-01-01). "Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer". Oncogene. 25 (34): 4675–4682. doi:10.1038/sj.onc.1209594. ISSN 0950-9232.
|NADH + H+ + CO2|